Please assess the completion status of the following clinical trial:

Trial Title: Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
The key inclusion criteria are:~1. Male or female adult de novo kidney, kidney-pancreas or kidney-islet, or kidney-liver transplant recipients~2. Functioning graft within 28 days after transplantation (creatinine having decreased to \<200 micromol/l without the need for dialysis)~3. Being on standard triple immunosuppression including a calcineurin antagonist (cyclosporine or tacrolimus), mycophenolate (MMF or MPA) and steroids, with or without induction treatment with basiliximab or anti-thymocyte globulin~Key exclusion criteria are:~1. Age \<18 years~2. Rising creatinine after initial drop \<200 micromol/l or creatinine \>200 micromol/l at baseline~3. Evidence of early acute rejection, either suspected clinically and/or proven by biopsy~4. Presence of severe osteoporosis as evidenced by a T score \<-4 at the hip, femoral neck or any of the 4 vertebrae L1 to L4~5. Evidence of severe hyper- or hypoparathyroidism (iPTH \>800 ng/l or \<10 ng/l)~6. Hypocalcemia (total calcium \<1.8 mmol/l) or hypercalcemia (total calcium \>2.7 mmol/l)~7. Steroid-free de novo immunosuppression scheme

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): 60 mg denosumab s.c. at baseline and after 6 months
- Control (Type: NO_INTERVENTION): No treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).